Employing PSI™ to Identify Optimal Bi-Specific Antibody Candidates

Learn how PSI can help you reveal functional immune-tumor interaction and mechanism of therapy to advise lead choice.

Your data is in safe hands: we'll never sell it to third parties and you may always unsubscribe. Privacy Policy.

Application of bispecific antibody constructs to improve immunotherapy success

Recent clinical progress in immunooncology significantly improved clinical outcomes for many patients with hard-to-treat malignant tumors, leading to partial and complete remission and long-term survival in a fraction of patients. However, a large number of patients do not respond to these treatments, creating an urgent need for novel strategies to enhance the efficacy of immunotherapies.

  • Highlight the use of IsoPlexis’ Polyfunctional Strength Index, PSI™, a single-cell cytokinebased metric of cellular potency, in the context of pre-clinical assessment of bispecific antibodies
  • Identify subtle differences in quality of novel bispecific antibody constructs relative to controls, utilizing the PSI of the potent T cell subsets engaged
  • Demonstrate that PSI can improve the choice of lead bispecific immunotherapeutic products by identifying key differences in the therapies’ cytokine-based mechanisms at the single-cell level